Ask what a prescription costs and you will get a different answer depending on who you ask, on the same day, for the same box of pills. Not slightly different — several times over. That is not a failure of the question. It is the structure of the market, and the reason it exists has a name most people have never heard.
The middleman almost nobody can name
A pharmacy benefit manager sits between the drug company, the insurer and the pharmacy. It decides which drugs a plan covers, negotiates rebates from manufacturers, sets what the pharmacy is reimbursed, and increasingly owns the pharmacy as well.
The FTC also found those PBMs are now vertically integrated with the largest health insurers and with retail and specialty pharmacies — and that pharmacies affiliated with the three biggest account for nearly 70% of all specialty drug revenue. The same corporate family can own the insurer deciding what is covered, the PBM setting the reimbursement, and the pharmacy receiving it.
Why the same drug has several prices at once
On a single day, one drug can carry: a list price set by the manufacturer, a net price after confidential rebates, a reimbursement rate the PBM pays the pharmacy, a copay the insured patient pays, a cash price for someone without insurance, and a discount-card price. These are not variations on a number. They are six different numbers produced by six different contracts, most of which are confidential.
The gap between list and net has a name in the industry — the gross-to-net bubble — and it exists because rebates are negotiated privately. A manufacturer can raise a list price and hand most of the increase back as a rebate, so the headline rises while the net barely moves. Anyone paying a percentage of list, which includes many people with deductibles and every uninsured person paying cash, pays against the inflated number.
This is the part worth being angry about, and it is also the part that most directly harms the reader of this site. If you have no insurance, you are outside every one of those negotiated arrangements. You are quoted a price built for a system you are not in.
PBMs did not appear from nowhere and they do exert real downward pressure. Aggregating the buying power of millions of members against a manufacturer with a patent monopoly is a genuine function, and the low US generic prices in the RAND data are partly their doing. The industry disputes the FTC's framing, and the FTC's own report is an interim staff report rather than a final finding or a court judgment.
The criticism that survives all of that is not “middlemen exist”. It is that the arrangements are confidential, so nobody outside them — including the patient, the prescriber and often the pharmacist — can see what anything actually costs.
The one price that is not a secret
There is a number in all of this that is public, and it is the reason this site can exist.
CMS surveys retail pharmacies and asks what they actually paid their wholesaler for a drug. The average is published weekly, free, in the public domain, as the National Average Drug Acquisition Cost. It is not a price anyone can buy at — it excludes every cost of running a pharmacy — but it is a floor that no contract can hide.
Put a cash price next to it and the arithmetic stops being mysterious. A modest markup is a pharmacy operating. A multiple is something else, and you can go and look at it yourself. We wrote a fuller explanation of NADAC for anyone who wants the detail.
What you can actually do
Not much about the structure. Quite a lot about your own prescription.
Ask the cash price even if you have insurance — it is sometimes below the copay, and a pharmacy will not always volunteer that. Compare pharmacies, because reimbursement rates and margins differ enormously between them for identical stock. Consider mail-order pharmacies that publish their arithmetic rather than quoting a figure. And check whether the drug is sold over the counter at all, which takes you outside the entire apparatus.
Look your drug up and see what the gap is.